Prevention of pertussis: Recommendations derived from the second Global Pertussis Initiative roundtable meeting

Vaccine

Volumn 25, Issue 14, 2007, Pages 2634-2642

  Forsyth, Kevin D ^a   Wirsing von Konig, Carl Heinz ^b   Tan, Tina ^c   Caro, Jaime ^d   Plotkin, Stanley ^e,f  

^a FLINDERS UNIVERSITY   (Australia)

^b Institut fur Hygiene und Laboratoriumsmedizin   (Germany)

^c NORTHWESTERN UNIVERSITY   (United States)

^d CARO RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f SANOFI PASTEUR   (France)

Author keywords

Adolescents; Adults; Epidemiology; Health economics; Immunization strategies; Infants; Infection; Pertussis; Reporting; Transmission

Indexed keywords

ACELLULAR VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS VACCINE;

ARTICLE; BACTERIAL TRANSMISSION; BORDETELLA PERTUSSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; ECONOMIC ASPECT; FEASIBILITY STUDY; HUMAN; IMMUNIZATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; PERTUSSIS; PRIORITY JOURNAL; PROPHYLAXIS; SKIN REDNESS; STANDARDIZATION; VACCINATION; VULNERABLE POPULATION;

ADOLESCENT; ADULT; BACTERIAL TYPING TECHNIQUES; BORDETELLA PERTUSSIS; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; HUMANS; VACCINATION; WHOOPING COUGH;

EID: 33947160992     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.12.017     Document Type: Article

References (77)

1. Forsyth K., Nagai M., Lepetic A., and Trindade E. Pertussis immunization in the global pertussis initiative international region: recommended strategies and implementation considerations. Pediatr Infect Dis J 24 (2005) S93-S97
2. Forsyth K.D., Campins-Marti M., Caro J., Cherry J.D., Greenberg D., Guiso N., et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 39 (2004) 1802-1809
3. Global Immunization Data 2004. World Health Organization. Available at: http://www.who.int/immunization_monitoring/data/GlobalImmunizationData.pdf#search=%222004%20global%20immunization%20pertussis%22 [accessed 14 September, 2006].
4. Halperin S.A. Pertussis immunization for adolescents: what are we waiting for?. Can J Infect Dis Med Microbiol 12 (2001) 74-76
5. Crowcroft N.S., and Pebody R.G. Recent developments in pertussis. Lancet 367 (2006) 1926-1936
6. O'Brien J.A., and Caro J.J. Hospitalization for pertussis: profiles and case costs by age. BMC Infect Dis 5 (2005) 57
7. Cherry J.D. The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative study. Curr Probl Pediatr 14 (1984) 1-78
8. Centers for Disease Control and Prevention. Pertussis-United States, 1997-2000. Morb Mortal Wkly Rep 51 (2002) 73-76
9. Centers for Disease Control and Prevention. Pertussis-United States, 2001-2003. Morb Mortal Wkly Rep 54 (2005) 1283-1286
10. Stanbridge T.N., and Preston N.W. Variation of serotype in strains of Bordetella pertussis. J Hyg (Lond) 73 (1974) 305-310
11. Goldman S., Hanski E., and Fish F. Spontaneous phase variation in Bordetella pertussis is a multistep non-random process. EMBO J 3 (1984) 1353-1356
12. Musser J.M., Hewlett E.L., Peppler M.S., and Selander R.K. Genetic diversity and relationships in populations of Bordetella spp. J Bacteriol 166 (1986) 230-237
13. van der Zee A., Mooi F., Van Embden J., and Musser J. Molecular evolution and host adaptation of Bordetella spp.: phylogenetic analysis using multilocus enzyme electrophoresis and typing with three insertion sequences. J Bacteriol 179 (1997) 6609-6617
14. Schouls L.M., van der Heide H.G., Vauterin L., Vauterin P., and Mooi F.R. Multiple-locus variable-number tandem repeat analysis of Dutch Bordetella pertussis strains reveals rapid genetic changes with clonal expansion during the late 1990s. J Bacteriol 186 (2004) 5496-5505
15. Weber C., Boursaux-Eude C., Coralie G., Caro V., and Guiso N. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol 39 (2001) 4396-4403
16. Heininger U., Frei R., Cherry J.D., and Stehr K. Comparison of pulsed field gel electrophoresis patterns of Bordetella pertussis isolates from unvaccinated children with severe or mild pertussis. Pediatr Infect Dis J 23 (2004) 211-217
17. Grimprel E., Begue P., Anjak I., Njamkepo E., Francois P., and Guiso N. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Clin Diagn Lab Immunol 3 (1996) 93-97
18. Guiso N., Begue P., and Cohen R. Comparison of pertussis antibody levels in children up to 5 years of age primed at 2, 3, 4 months and booster in a second year of life with either DTPa or DTPw based combination vaccines in France. 40th ICAAC. Toronto, Canada, September 17-20, 2000 (2000) [abstract 62]
19. Kodama A., Kamachi K., Horiuchi Y., Konda T., and Arakawa Y. Antigenic divergence suggested by correlation between antigenic variation and pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates in Japan. J Clin Microbiol 42 (2004) 5453-5457
20. Glismann S., Ronne T., and Tozzi A. The EUVAC-NET project: creation and operation of a surveillance community network for vaccine preventable infectious diseases. Euro Surveill 6 (2001) 94-98
21. Celentano L.P., Massari M., Paramatti D., Salmaso S., and Tozzi A.E. Resurgence of pertussis in Europe. Pediatr Infect Dis J 24 (2005) 761-765
22. Versteegh F.G., Weverling G.J., Peeters M.F., Wilbrink B., Veenstra-van Schie M.T., van Leeuwen-Gerritsen J.M., et al. Community-acquired pathogens associated with prolonged coughing in children: a prospective cohort study. Clin Microbiol Infect 11 (2005) 801-807
23. Riffelmann M., Wirsing von Konig C.H., Caro V., and Guiso N. Nucleic acid amplification tests for diagnosis of Bordetella infections. J Clin Microbiol 43 (2005) 4925-4929
24. Horby P., Macintyre C.R., McIntyre P.B., Gilbert G.L., Staff M., Hanlon M., et al. A boarding school outbreak of pertussis in adolescents: value of laboratory diagnostic methods. Epidemiol Infect 133 (2005) 229-236
25. Versteegh F.G., Mertens P.L., de Melker H.E., Roord J.J., Schellekens J.F., and Teunis P.F. Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis. Epidemiol Infect 133 (2005) 737-748
26. Ntezayabo B., De Serres G., and Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 22 (2003) 22-27
27. Greenberg D.P. Pertussis in adolescents: increasing incidence brings attention to the need for booster immunization of adolescents. Pediatr Infect Dis J 24 (2005) 721-728
28. Gzyl A., Augustynowicz E., Rabczenko D., Gniadek G., and Slusarczyk J. Pertussis in Poland. Int J Epidemiol 33 (2004) 358-365
29. Klement E., Uliel L., Engel I., Hasin T., Yavzori M., Orr N., et al. An outbreak of pertussis among young Israeli soldiers. Epidemiol Infect 131 (2003) 1049-1054
30. Bisgard K.M., Pascual F.B., Ehresmann K.R., Miller C.A., Cianfrini C., Jennings C.E., et al. Infant pertussis: who was the source?. Pediatr Infect Dis J 23 (2004) 985-989
31. Southern J., Andrews N., Burrage M., and Miller E. Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine 23 (2005) 3829-3835
32. Pichichero M.E., Rennels M.B., Edwards K.M., Blatter M.M., Marshall G.S., Bologa M., et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 293 (2005) 3003-3011
33. Vergara R., Tregnaghi M., Ussher J., Navarro S., Ruttimann R., Potin M., et al. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr 164 (2005) 377-382
34. Halperin S.A. Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implications for the United States. Pediatr Infect Dis J 24 (2005) S141-S146
35. Halperin S.A., Sweet L., Baxendale D., Neatby A., Rykers P., Smith B., et al. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?. Pediatr Infect Dis J 25 (2006) 195-200
36. Pichichero M.E., Casey J.R., Francis A.B., Marsocci S.M., Murphy M., Hoeger W., et al. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules. Clin Pediatr (Phil) 45 (2006) 613-620
37. Broder K.R., Cortese M.M., Iskander J.K., Kretsinger K., Slade B.A., Brown K.H., et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 (2006) 1-34
38. Heininger U., and Cherry J.D. Pertussis immunisation in adolescents and adults-Bordetella pertussis epidemiology should guide vaccination recommendations. Expert Opin Biol Ther 6 (2006) 685-697
39. Edelman K.J., He Q., Makinen J.P., Haanpera M.S., Nguyen Tran Minh N., Schuerman L., et al. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis 39 (2004) 179-185
40. Smith N.M., Bresee J.S., Shay D.K., Uyeki T.M., Cox N.J., and Strikas R.A. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 (2006) 1-42
41. Lee G.M., Lebaron C., Murphy T.V., Lett S., Schauer S., and Lieu T.A. Pertussis in adolescents and adults: should we vaccinate?. Pediatrics 115 (2005) 1675-1684
42. Purdy K.W., Hay J.W., Botteman M.F., and Ward J.I. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis 39 (2004) 20-28
43. Brody JE. Protected from pertussis? Most likely, you're not. New York Times; 2006, February 7.
44. Altman LK. New booster vaccine urged to fight whooping cough. New York Times; 2005, July 1.
45. Ward J.I., Cherry J.D., Chang S.J., Partridge S., Lee H., Treanor J., et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 353 (2005) 1555-1563
46. Le T., Cherry J.D., Chang S.J., Knoll M.D., Lee M.L., Barenkamp S., et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis 190 (2004) 535-544
47. Bonhoeffer J., Bar G., Riffelmann M., Soler M., and Heininger U. The role of Bordetella infections in patients with acute exacerbation of chronic bronchitis. Infection 33 (2005) 13-17
48. Centers for Disease Control and Prevention. ACIP votes to recommend use of combined tetanus, diphtheria and pertussis (Tdap) vaccine for adults. Available at: http://www.cdc.gov/nip/vaccine/tdap/tdap_adult_recs.pdf [accessed February 27, 2006].
49. Elliott E., McIntyre P., Ridley G., Morris A., Massie J., McEniery J., et al. National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatr Infect Dis J 23 (2004) 246-252
50. Mertsola J., Ruuskanen O., Eerola E., and Viljanen M.K. Intrafamilial spread of pertussis. J Pediatr 103 (1983) 359-363
51. Floret D. Pediatric deaths due to community-acquired bacterial infection. Survey of French pediatric intensive care units. Arch Pediatr 8 Suppl. 4 (2001) 705s-711s
52. Van Rie A., and Hethcote H.W. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine 22 (2004) 3154-3165
53. Centers for Disease Control and Prevention. Hepatitis B vaccination among high-risk adolescents and adults-San Diego, California, 1998-2001. MMWR Morb Mortal Wkly Rep 51 (2002) 618-621
54. Centers for Disease Control and Prevention. Hepatitis B vaccination coverage among adults-United States, 2004. MMWR Morb Mortal Wkly Rep 55 (2006) 509-511
55. Austrailian immunisation handbook, 8th ed. National Health and Medical Research Council; 2003.
56. Healy C.M., Munoz F.M., Rench M.A., Halasa N.B., Edwards K.M., and Baker C.J. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 190 (2004) 335-340
57. Fischer G.W., Ottolini M.G., and Mond J.J. Prospects for vaccines during pregnancy and in the newborn period. Clin Perinatol 24 (1997) 231-249
58. Van Rie A., Wendelboe A.M., and Englund J.A. Role of maternal pertussis antibodies in infants. Pediatr Infect Dis J 24 (2005) S62-S65
59. Elahi S., Buchanan R.M., Babiuk L.A., and Gerdts V. Maternal immunity provides protection against pertussis in newborn piglets. Infect Immun 74 (2006) 2619-2627
60. Hanlon M., Nambiar R., Kakakios A., McIntyre P., Land M., and Devine P. Pertussis antibody levels in infants immunized with an acellular pertussis component vaccine, measured using whole-cell pertussis ELISA. Immunol Cell Biol 78 (2000) 254-258
61. Lagos R., Munoz A., Dumas R., Pichon S., Zambrano B., Levine M., et al. Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in presence of maternal antibodies. Vaccine 21 (2003) 3730-3733
62. Rowe J., Poolman J.T., Macaubas C., Sly P.D., Loh R., and Holt P.G. Enhancement of vaccine-specific cellular immunity in infants by passively acquired maternal antibody. Vaccine 22 (2004) 3986-3992
63. Cherry J.D. Pertussis in the preantibiotic and prevaccine era, with emphasis on adult pertussis. Clin Infect Dis 28 Suppl. 2 (1999) S107-S111
64. Halperin S.A., King J., Law B., Mills E., and Willems P. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. Clin Infect Dis 28 (1999) 995-1001
65. Herzig P., Hartmann C., Fischer D., Weil J., von Kries R., Giani G., et al. Pertussis complications in Germany-3 years of hospital-based surveillance during the introduction of acellular vaccines. Infection 26 (1998) 227-231
66. de Melker H.E., Conyn-van Spaendonck M.A., Rumke H.C., van Wijngaarden J.K., Mooi F.R., and Schellekens J.F. Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg Infect Dis 3 (1997) 175-178
67. Khalak R., Pichichero M.E., and D'Angio C.T. Three-year follow-up of vaccine response in extremely preterm infants. Pediatrics 101 (1998) 597-603
68. Kirmani K.I., Lofthus G., Pichichero M.E., Voloshen T., and D'Angio C.T. Seven-year follow-up of vaccine response in extremely premature infants. Pediatrics 109 (2002) 498-504
69. Englund J.A., Anderson E.L., Reed G.F., Decker M.D., Edwards K.M., Pichichero M.E., et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 96 (1995) 580-584
70. Pichichero M.E., Edwards K.M., Anderson E.L., Rennels M.B., Englund J.A., Yerg D.E., et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics 105 (2000) e11
71. Diez-Domingo J., Delgado J.D., Ballester A., Baldo J.M., Planelles M.V., Garces M., et al. Immunogenicity and reactogenicity of a combined adsorbed tetanus toxoid, low dose diphtheria toxoid, five component acellular pertussis and inactivated polio vaccine in six-year-old children. Pediatr Infect Dis J 24 (2005) 219-224
72. Scheifele D.W., Halperin S.A., Ochnio J.J., Ferguson A.C., and Skowronski D.M. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. Pediatr Infect Dis J 24 (2005) 1059-1066
73. Nilsson L., Faldella G., Jacquet J.M., Storsaeter J., Silfverdal S.A., and Ekholm L. A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age. Scand J Infect Dis 37 (2005) 221-229
74. Lee G.M., Lett S., Schauer S., LeBaron C., Murphy T.V., Rusinak D., et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis 39 (2004) 1572-1580
75. Ward A., Caro J., Bassinet L., Housset B., O'Brien J.A., and Guiso N. Health and economic consequences of an outbreak of pertussis among healthcare workers in a hospital in France. Infect Control Hosp Epidemiol 26 (2005) 288-292
76. Scuffham P.A., and McIntyre P.B. Pertussis vaccination strategies for neonates-an exploratory cost-effectiveness analysis. Vaccine 22 (2004) 2953-2964
77. Tan T., Halperin S., Cherry J.D., Edwards K., Englund J.A., Glezen P., et al. Pertussis immunization in the global pertussis initiative North American region: recommended strategies and implementation considerations. Pediatr Infect Dis J 24 (2005) S83-S86